AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19941334 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale at 3, 6, and 12 months
Number of subjects: 85
Study 19941334 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of muscle ache and cramps
Number of subjects: 85
Study 19941334 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of physical residua
Number of subjects: 85
Study 18976032 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention deficit hyperactivity disorder symptoms screening
Number of subjects: 2000
Study 18976032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactive-impulsive type of attention deficit hyperactivity
Number of subjects: 2000
Study 18976032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined type of attention deficit hyperactivity
Number of subjects: 2000
Study 16620266 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric low-fat diet
Number of subjects: 13
Study 16620266 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes diet
Number of subjects: 13
Study 16620266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 13
Study 12853344 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD bolus (vincristine 0.4 mg i.v., doxorubicin 9 mg/m² i.v., dexamethasone 40 mg p.o. daily for 4 days)
Number of subjects: 259
Study 12853344 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD doxil (vincristine 2 mg i.v., liposomal doxorubicin 40 mg/m² i.v. on day 1, dexamethasone 40 mg p.o. daily for 4 days)
Number of subjects: 259
Study 12853344 — intervention group
Group type: COMPARATOR
Intervention: VAD bolus
Number of subjects: 259
Study 12853344 — intervention group
Group type: COMPARATOR
Intervention: VAD doxil
Number of subjects: 259
Study 11148800 — intervention group
Group type: COMPARATOR
Intervention: Fluoride therapy
Number of subjects: 1429
Study 8823827 — intervention group
Group type: EXPERIMENTAL
Intervention: QT = ACT dual sensor VVIR mode
Number of subjects: 4
Study 8823827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ACT threshold dual sensor mode
Number of subjects: 4
Study 8823827 — intervention group
Group type: COMPARATOR
Intervention: QT only VVIR mode
Number of subjects: 4
Study 8823827 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimally programmed ACT setting
Number of subjects: 4
Study 8823827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threshold ACT setting
Number of subjects: 4
Study 8504233 — intervention group
Group type: EXPERIMENTAL
Intervention: Program A (guided by pain)
Number of subjects: 309
Study 8504233 — intervention group
Group type: EXPERIMENTAL
Intervention: Program B (intensive physical training, 'no pain, no gain')
Number of subjects: 309
Study 8504233 — intervention group
Group type: COMPARATOR
Intervention: Both programs
Number of subjects: 309
Study 3959249 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 34
Study 3959249 — intervention group
Group type: COMPARATOR
Intervention: Propantheline
Number of subjects: 34
Study 29458904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysmenorrhea group
Number of subjects: 184
Study 29458904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysmenorrhea group with vitamin D deficiency
Number of subjects: 184
Study 29458904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency group
Number of subjects: 184
Study 29458904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysmenorrhea patients
Number of subjects: 184
Study 29458904 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 26836220 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible duty-hour policies
Number of subjects: 4330
Study 26836220 — intervention group
Group type: COMPARATOR
Intervention: Standard duty-hour policies
Number of subjects: 4330
Study 25480673 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets
Number of subjects: 720
Study 25480673 — intervention group
Group type: COMPARATOR
Intervention: losartan potassium 50 mg
Number of subjects: 720
Study 25480673 — intervention group
Group type: COMPARATOR
Intervention: losartan potassium 100 mg
Number of subjects: 720
Study 25480673 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets + losartan potassium 50 mg
Number of subjects: 720
Study 25480673 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenyankangfu tablets + losartan potassium 100 mg
Number of subjects: 720
Study 22244574 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg escitalopram
Number of subjects: 44
Study 22244574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20145261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid
Number of subjects: 0
Study 20145261 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 0
Study 17715211 — intervention group
Group type: EXPERIMENTAL
Intervention: VML-670 (5-HT(1A) and 5-HT(1D) agonist)
Number of subjects: 288
Study 17715211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 17715211 — intervention group
Group type: EXPERIMENTAL
Intervention: VML-670
Number of subjects: 288
Study 15956360 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E2)
Number of subjects: 0
Study 12528088 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (37.5 +/- 13.5 mg/12 h)
Number of subjects: 26
Study 12528088 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (5.4 +/- 3.0 mg/d)
Number of subjects: 26
Study 12528088 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26
Study 12528088 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 26
Study 10736887 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated medical‐dental patient‐held record (PHR) issued to patients
Number of subjects: 369
Study 10736887 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated medical‐dental patient‐held record (PHR)
Number of subjects: 369
Study 7537286 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 to 16 mg/day
Number of subjects: 135
Study 7537286 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 135
Study 7537286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 7537286 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day
Number of subjects: 135
Study 2042757 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 60
Study 2042757 — intervention group
Group type: COMPARATOR
Intervention: Ketamine infusion
Number of subjects: 60
Study 45068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induced labor using amniotomy and oxytocin infusion with the Cardiff Infusion System Mark II
Number of subjects: 84
Study 45068 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous labor
Number of subjects: 84
Study 30855082 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person support intervention
Number of subjects: 415
Study 30855082 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote support intervention
Number of subjects: 415
Study 30855082 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 415
Study 31771714 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 0
Study 31771714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28081548 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of bevacizumab with second-line chemotherapy
Number of subjects: 184
Study 26175145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric pyrophosphate citrate (FPC, Triferic™) via hemodialysate
Number of subjects: 599
Study 26175145 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate (placebo)
Number of subjects: 599
Study 23374649 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting biodegradable polymer stent
Number of subjects: 2468
Study 23374649 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting permanent polymer stent
Number of subjects: 2468
Study 21394500 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 4 mg administered intravenously after each chemotherapy cycle for 60 months post-randomisation (six doses in the first 6 months, eight doses in the following 24 months and five doses in the final 30 months).
Number of subjects: 3340
Study 21394500 — intervention group
Group type: COMPARATOR
Intervention: Control group received neither additional treatment nor intravenous ZOL.
Number of subjects: 3340
Study 19013924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training methods (specifically 'The Knack' and 'The Perineal Lock')
Number of subjects: 0
Study 19013924 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (general)
Number of subjects: 0
Study 16627862 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 53
Study 16627862 — intervention group
Group type: COMPARATOR
Intervention: Control (nonrebreather bag-valve mask)
Number of subjects: 53
Study 14994569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (Group A)
Number of subjects: 14
Study 14994569 — intervention group
Group type: COMPARATOR
Intervention: No nitric oxide inhalation (Group B)
Number of subjects: 14
Study 10978060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic treatment using the 'forced air' method for 6 hours (cooling blanket with a flow of cool air at 10 degrees C)
Number of subjects: 17
Study 10978060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic treatment
Number of subjects: 17
Study 10978060 — intervention group
Group type: COMPARATOR
Intervention: Control group (56 patients matched for age, gender, initial stroke severity, body temperature on admission, and time from stroke onset to admission)
Number of subjects: 17
Study 8869682 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent (sodium lauryl sulphate) at 40 degrees C
Number of subjects: 20
Study 8869682 — intervention group
Group type: EXPERIMENTAL
Intervention: Detergent (sodium lauryl sulphate) at 20 degrees C
Number of subjects: 20
Study 8869682 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 20
Study 1739570 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at doses of 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, and 2.6 mg kg‐1
Number of subjects: 300
Study 1739570 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 300
Study 6377784 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole/fosfomycin
Number of subjects: 49
Study 6377784 — intervention group
Group type: COMPARATOR
Intervention: metronidazole/placebo
Number of subjects: 49
Study 28921778 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention 'Alcohol e-Health'
Number of subjects: 0
Study 28921778 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 27472252 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Jugular Vein
Number of subjects: 280
Study 27472252 — intervention group
Group type: COMPARATOR
Intervention: Subclavian Vein
Number of subjects: 280
Study 25666112 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective soccer headband
Number of subjects: 25
Study 25666112 — intervention group
Group type: COMPARATOR
Intervention: No headband
Number of subjects: 25
Study 23360359 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) 200 mg/d for 8 weeks
Number of subjects: 22
Study 23360359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21397383 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Volume Marked Bag (TVMB)
Number of subjects: 53
Study 21397383 — intervention group
Group type: COMPARATOR
Intervention: Adult Bag
Number of subjects: 53
Study 21397383 — intervention group
Group type: COMPARATOR
Intervention: Paediatric Bag
Number of subjects: 53
Study 18433304 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/d)
Number of subjects: 389
Study 18433304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 389
Study 16540798 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-LCPUFA formula with 17 mg DHA, 34 mg ARA, 85 mg ALA, and 860 mg LA per 100 kcal
Number of subjects: 78
Study 16540798 — intervention group
Group type: COMPARATOR
Intervention: Lower-LCPUFA formula with 8 mg DHA, 21 mg ARA, 110 mg ALA, and 1,000 mg LA per 100 kcal
Number of subjects: 78
Study 14575766 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (20 microg)
Number of subjects: 80
Study 14575766 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study 10885162 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 225
Study 8829094 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula and cereal
Number of subjects: 41
Study 8829094 — intervention group
Group type: COMPARATOR
Intervention: Formula alone
Number of subjects: 41
Study 1591828 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator (100 mg over 2 hours)
Number of subjects: 197
Study 1591828 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study 1591828 — intervention group
Group type: EXPERIMENTAL
Intervention: angioplasty
Number of subjects: 197
Study 1591828 — intervention group
Group type: COMPARATOR
Intervention: no angioplasty
Number of subjects: 197
Study 1591828 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator
Number of subjects: 197
Study 3901674 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus monitoring by a specialist nurse
Number of subjects: 152
Study 3901674 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 152
Study 3901674 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication plus cognitive therapy
Number of subjects: 152
Study 3901674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy alone
Number of subjects: 152
Study 30453332 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive (STI) therapy
Number of subjects: 11
Study 30453332 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 11
Study 30646152 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared financial incentives for patients and physicians
Number of subjects: 1000000
Study 30646152 — intervention group
Group type: COMPARATOR
Intervention: Trial control strategy (increased cholesterol level monitoring and use of electronic pill bottles)
Number of subjects: 1000000
Study 30646152 — intervention group
Group type: COMPARATOR
Intervention: Financial incentives for physicians
Number of subjects: 1000000
Study 30646152 — intervention group
Group type: COMPARATOR
Intervention: Financial incentives for patients
Number of subjects: 1000000
Study 30646152 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000000
Study 26745211 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy and family-based behavioral treatment (mean duration 70.04 days)
Number of subjects: 156
Study 26745211 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy and family-based behavioral treatment
Number of subjects: 156
Study 26745211 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant monotherapy and behavioral treatment
Number of subjects: 156
Study 24934962 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus bupropion
Number of subjects: 222
Study 24934962 — intervention group
Group type: COMPARATOR
Intervention: Varenicline plus placebo
Number of subjects: 222
Study 22129562 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication combinations (mirtazapine and venlafaxine)
Number of subjects: 665
Study 22129562 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 665
Study 20012484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 mcg twice daily
Number of subjects: 237
Study 20012484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 18843432 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training combined with coenzyme Q10 supplementation (200 mg/day)
Number of subjects: 14
Study 18843432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16640511 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 30
Study 16640511 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 30
Study 16640511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15022975 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic group by telephone conference call
Number of subjects: 66
Study 15022975 — intervention group
Group type: COMPARATOR
Intervention: Usual psychosocial care
Number of subjects: 66
Study 11192705 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine plus low-level exercise (Group B)
Number of subjects: 58
Study 11192705 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine alone (Group A)
Number of subjects: 58
Study 8630467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin levels in BAL fluid in patients with sarcoidosis
Number of subjects: 14
Study 8630467 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (9 participants)
Number of subjects: 14
Study 1705386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/day
Number of subjects: 114
Study 1705386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 640 mg/day
Number of subjects: 114
Study 1705386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 6366344 — intervention group
Group type: EXPERIMENTAL
Intervention: Efemoline eyedrops (fluorometholone 0.1% + tetryzoline 0.25%)
Number of subjects: 35
Study 6366344 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 35
Study 31540611 — intervention group
Group type: EXPERIMENTAL
Intervention: Illicit opioid use
Number of subjects: 37
Study 31540611 — intervention group
Group type: COMPARATOR
Intervention: Early clinic hours (07:00-09:00)
Number of subjects: 37
Study 31540611 — intervention group
Group type: COMPARATOR
Intervention: Late clinic hours (12:00-13:00)
Number of subjects: 37
Study 31540611 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic hours (07:00-11:30)
Number of subjects: 37
Study 29316996 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 40
Study 29316996 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 26872008 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 125 mg/m2 and cisplatin 60 mg/m2 (high-dose group)
Number of subjects: 41
Study 26872008 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 80 mg/m2 and cisplatin 50 mg/m2 (low-dose group)
Number of subjects: 41
Study 26872008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-dose and low-dose groups
Number of subjects: 41
Study 23338668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 4 % spray gel applied two or three times daily for 3 days
Number of subjects: 39
Study 21831478 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscopy
Number of subjects: 23
Study 21831478 — intervention group
Group type: COMPARATOR
Intervention: Flexible fiber-optic laryngoscopy
Number of subjects: 23
Study 20078213 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/rAd5 vaccination regimen
Number of subjects: 324
Study 20078213 — intervention group
Group type: COMPARATOR
Intervention: rAd5 alone
Number of subjects: 324
Study 17324628 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of carbohydrates per day
Number of subjects: 20
Study 17324628 — intervention group
Group type: COMPARATOR
Intervention: 20 g of carbohydrates per day
Number of subjects: 20
Study 16132885 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with glucose/lipid ratio of 50/50
Number of subjects: 47
Study 16132885 — intervention group
Group type: COMPARATOR
Intervention: TPN with glucose/lipid ratio of 80/20
Number of subjects: 47
Study 12137830 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation (TUNA)
Number of subjects: 33
Study 12137830 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (urethrocystoscopy)
Number of subjects: 33
Study 10448776 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol, thioridazine, and lorazepam
Number of subjects: 58
Study 10448776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 8578801 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf(66)n synthetic malaria vaccine
Number of subjects: 0
Study 2112167 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment
Number of subjects: 106
Study 2112167 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 106
Study 526404 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 19
Study 526404 — intervention group
Group type: COMPARATOR
Intervention: methyldopa
Number of subjects: 19
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 20-24 years
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 25-29 years
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 30-34 years
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level primary
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level secondary
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level college diploma and above
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly income 1001-2000 Ethiopian birr
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly income 2001-3000 Ethiopian birr
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Years in marriage 1-2 years
Number of subjects: 429
Study 31164156 — intervention group
Group type: EXPERIMENTAL
Intervention: Last time of abortion 1-2 years
Number of subjects: 429